Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats

Hims & Hers Super Bowl controversy: What the ad left out about its 'alternative' weight-loss drugs
The telehealth company Hims & Hers put out a Super Bowl ad that skimped on clarifying that its compounded semaglutide medications aren't FDA-approved.
Hims & Hers Super Bowl ad sparks controversy
CNBC's Brandon Gomez joins 'Squawk on the Street' to break down the controversy around Hims & Hers Super Bowl ads.
Hims & Hers Super Bowl Spot Draws Drug-Industry Backlash
Telehealth provider Hims & Hers Health is defending its planned Super Bowl ad, which is styled as a political manifesto against weight-loss treatments priced “for profits, not patients,” after critici
Hims & Hers Super Bowl ad stirs up controversy with lawmakers
Hims & Hers Health (HIMS) stock moves a notch higher Monday morning after the company's weight-loss drug ad played during the Super Bowl. The commercial's airing raised concerns from health experts and US lawmakers over the exclusion of potential side effects tied to GLP-1 weight-loss treatments in the advertisement.
Ozempic, Wegovy maker responds to Hims & Hers Super Bowl ad
Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.
Hims & Hers Stock Bounces After Super Bowl Ad
Shares of Hims & Hers rose 5.2% Monday after the telehealth provider ran an advertisement on Super Bowl Sunday highlighting the company's efforts to fight the obesity epidemic in America. But Heard on
Hims & Hers Set To Run Impactful Super Bowl Ad
Telehealth company Hims & Hers' first Super Bowl ad is provocative and effective in building awareness of its weight loss offerings in a way that will generate buzz.
GLP-1 ad battle—Ozempic and Wegovy maker responds to Hims & Hers Super Bowl debut
Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.
Super Bowl ad sparks controversy over cut-rate Wegovy alternative
Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived deal for consumers.
Hims & Hers Takes Aim At Big Pharma In Controversial Super Bowl Ad — Retail Loves The Fight
Shares of Hims & Hers Health Inc. jumped nearly 4% in early premarket trading Monday, on track for fresh record highs, after the company aired a provocative Super Bowl ad that targeted Big Pharma and the U.
FiercePharma3h
Pfizer wins 2025 Super Bowl with ad's 'likeability,' while Hims & Hers' spot takes engagement crown: analysts
Hims & Hers' “Sick of the System” spot not only generated the highest engagement of all pharma-related ads that aired during ...
Hims & Hers Health: Explosive Growth Potential Ahead
Hims & Hers' future growth is expected from personalized solutions, with potential to expand the subscriber base by millions.
San Francisco company airs controversial Super Bowl ad despite multiple objections
Hims & Hers, a San Francisco-headquartered telehealth company, ran its controversial Super Bowl commercial despite multiple ...
Why Hims & Hers Health Stock Crushed Novo Nordisk and Viking Therapeutics Today
Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The ...
Hims & Hers Health: Meme Potential Could Propel Explosive Growth
Hims has a great deal of meme potential, which could benefit the company by effectively acting as free advertising. Read more ...